OLIGOMERIX has a significant portfolio of patents and pending applications (collectively its intellectual property or IP) The Company employs a number of tactics to protect its intellectual property, including (1) broadly defining and patenting all processes and methods, (2) patenting each molecular entity, (3) maintaining close control over all trade secrets and (4) executing trademarks, as appropriate. To date, the Company has received six issued patents and has pending or patent applications supporting its core technology (four patent families), and several pending for related technologies

• Tau oligomer in vitro assay - full application submitted for use of tau oligomers as a target for development of therapeutics for AD, priority date February 2006
• Biomarker assays - full application filed, priority date February 2007
• Model memory assay - provisional application submitted jointly with Columbia University Medical Center (CUMC) filed, priority date September 2007
• Tau methods and assays (HTS) - provisional application filed, priority date March 2008

Several issued patents and pending applications supporting core IP in drug discovery and diagnostics.